NDC 69097-890
Lanreotide Acetate
Lanreotide Acetate
Lanreotide Acetate is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Cipla Usa Inc.. The primary component is Lanreotide Acetate.
| Product ID | 69097-890_3b76bee0-aeac-4086-801b-e5b6acfdac6c |
| NDC | 69097-890 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Lanreotide Acetate |
| Generic Name | Lanreotide Acetate |
| Dosage Form | Injection |
| Route of Administration | SUBCUTANEOUS |
| Marketing Start Date | 2021-12-24 |
| Marketing Category | NDA / |
| Application Number | NDA215395 |
| Labeler Name | Cipla USA Inc. |
| Substance Name | LANREOTIDE ACETATE |
| Active Ingredient Strength | 90 mg/.3mL |
| Pharm Classes | Somatostatin Analog [EPC],Somatostatin Receptor Agonists [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |